Medical articles today

/* 728x15, */

PLC Medical Systems To Demonstrate RenalGuard R At EuroPCR 2009

/* 468x60, */

PLC Systems Inc. (OTC Buletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, announced that it testament demonstrate its RenalGuard System(TM) at EuroPCR, the annual clambake of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 19-22, 2009, in Barcelona, Spain. Expanded than 11,000 clinicians and professionals are expected to attend this event.
In addition, RenalGuard(R) will be included as division of a live event transmission from Infirmary Clinico San Carlos, Madrid, Spain during the meeting. The interventional cardiologists involved in the circumstances way to instruct how RenalGuard is used to balm prevent Contrast-Induced Nephropathy (CIN) in a patient with impaired renal avail undergoing a Percutaneous Coronary Intervention (PCI).
"Following the spirit of EuroPCR, our commitment during these vital cases is to provide substantial clinical education to EuroPCR attendees," stated Dr. Javier Escaned, Consultant Interventional Cardiologist, Infirmary Clinico. "I chew over that creating awareness of the botheration of CIN and disseminating new information on how to prevent it are too important."
Point R. Tauscher, head of the state and manager executive officer of PLC Systems, said, "We are authentic pleased to be presenting RenalGuard to this chief audience, and chiefly satisfied that Dr. Escaned will be demonstrating a animate case illustrating how RenalGuard works and how it may facilitate patients. CIN is a significant and growing keeping worldwide, and we are very encouraged by the coming that RenalGuard could remedy it."
Currently, RenalGuard is the subject of an investigator-sponsored proof to recite its efficacy in mitigating against CIN at the University of Milan-Centro Cardiologico Monzino (CCM). The analysis is designed to provide an assessment of the potential benefits of induced diuresis with matched hydration therapy compared to criterion overnight hydration, a prevalent method of treatment in the EU, in the prevention of CIN in patients undergoing cardiac catheterization procedures and percutaneous coronary interventions with baseline impairment in renal function. The CIN-prevention therapy of induced diuresis and matched hydration therapy will be if using RenalGuard.
PLC received the CE Mark Certificate for the RenalGuard Step in December 2007, and concluded its captain safety test in the U.S. behind in 2007. The company has received full approval from the FDA to commence a U.S. pivotal probation to read the effectiveness of RenalGuard in the prevention of CIN. In March 2008, PLC signed its first off international distribution treaty for RenalGuard with Artech s.r.l., Cavezzo, Italy for distribution of its RenalGuard Action into Italy, and in May 2009, PLC announced its moment European distributor, IZASA Distribuciones Tecnicas S.A., headquartered in Barcelona, Spain, for the distribution of RenalGuard in Spain.
About PLC Systems Inc.
PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Passion Laser System, which cardiac surgeons apply to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard, is approved for sale in the EU as a common fluid balancing device.
This press release contains "forward-looking" statements. For this purpose, any statements contained in this press proceeds that relate to prospective events or developments are deemed to be forward-looking statements. Subject such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to button down forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may vote to revise forward-looking statements in the future, we specifically disclaim any debt to do so, still whether our estimates change, and you should not rely on these forward-looking statements as representing our views as of any day subsequent to the generation of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a conclusion of a variety of valuable factors, including that we may not corral de rigueur regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, we may be unable to hoist sufficient funds in the imminent to device our business design and/or commence our planned U.S. clinical trial for RenalGuard, the ongoing clinical research in Italy and the deliberate forthcoming U.S. clinical check for RenalGuard as a sheltered and cogent prevention slogan for contrast induced nephropathy may not be completed in a timely fashion, if at all, or, provided these clinical trials are completed, they may not produce clinically momentous or important results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may alter the marketplace for our products, regulatory approval requirements may interest the mart for our products, and supplementary risk factors described in the "Forward Looking Statements" abbreviate of our Annual Announcement on Form 10-K for the year ended December 31, 2008, and our other SEC reports.
PLC Systems, PLC Medical Systems, PLC and CO2 Feelings Laser, RenalGuard and RenalGuard Course are trademarks of PLC Systems Inc.
Source: PLC Systems Inc
/* 468x60, */


renalguard, renalguard europcr, demonstrate renalguard, renalguard product, distribution renalguard, renalguard ongoing, renalguard artech, renalguard approved, renalguard renalguard, renalguard sheltered
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy